US 11,707,518 B2
Method of treating, reducing, or alleviating a medical condition in a patient
Gholam A. Peyman, Sun City, AZ (US)
Filed by Gholam A. Peyman, Sun City, AZ (US)
Filed on Mar. 18, 2022, as Appl. No. 17/699,055.
Application 17/699,055 is a continuation in part of application No. 17/180,784, filed on Feb. 20, 2021.
Application 17/180,784 is a continuation in part of application No. 16/861,128, filed on Apr. 28, 2020, granted, now 10,925,889, issued on Feb. 23, 2021.
Claims priority of provisional application 63/162,986, filed on Mar. 18, 2021.
Claims priority of provisional application 63/177,916, filed on Apr. 21, 2021.
Claims priority of provisional application 63/181,948, filed on Apr. 29, 2021.
Claims priority of provisional application 63/209,331, filed on Jun. 10, 2021.
Claims priority of provisional application 63/221,852, filed on Jul. 14, 2021.
Claims priority of provisional application 63/239,927, filed on Sep. 1, 2021.
Claims priority of provisional application 63/306,042, filed on Feb. 2, 2022.
Claims priority of provisional application 63/039,959, filed on Jun. 16, 2020.
Claims priority of provisional application 63/055,770, filed on Jul. 23, 2020.
Claims priority of provisional application 63/077,677, filed on Sep. 13, 2020.
Claims priority of provisional application 63/106,319, filed on Oct. 27, 2020.
Claims priority of provisional application 63/131,761, filed on Dec. 29, 2020.
Claims priority of provisional application 62/839,738, filed on Apr. 28, 2019.
Claims priority of provisional application 63/016,258, filed on Apr. 27, 2020.
Prior Publication US 2022/0202933 A1, Jun. 30, 2022
Int. Cl. A61K 39/215 (2006.01); A61K 31/155 (2006.01); A61K 31/422 (2006.01); A61K 31/506 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61K 35/13 (2015.01); A61K 35/66 (2015.01); A61K 35/74 (2015.01); A61K 35/76 (2015.01); A61K 36/06 (2006.01); A61K 39/00 (2006.01); C12N 1/00 (2006.01); C12N 1/02 (2006.01)
CPC A61K 39/215 (2013.01) [A61K 31/155 (2013.01); A61K 31/422 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 35/13 (2013.01); A61K 35/66 (2013.01); A61K 35/74 (2013.01); A61K 35/76 (2013.01); A61K 36/06 (2013.01); A61K 39/00 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C12N 1/00 (2013.01); C12N 1/02 (2013.01); A61K 2039/543 (2013.01); A61K 2039/55511 (2013.01); C12N 2501/999 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A method for producing an immunogenic coronavirus composition, the method comprising:
growing coronaviruses on a cell culture or other appropriate medium;
harvesting the coronaviruses from the cell culture or other appropriate medium;
killing the coronaviruses in the cell culture or other appropriate medium with a dose of methylene blue that is greater than 2.0 micrograms per milliliter so as to damage the RNA and/or the DNA of the coronaviruses, wherein the coronaviruses remain in contact with the methylene blue for a period of time that is sufficient for the methylene blue to penetrate the coronaviruses and attach to RNA or DNA of the coronaviruses and prevent multiplication of the coronaviruses;
separating the dead coronaviruses from a remainder of the cell culture or other appropriate medium using a filter and/or centrifuge;
adding antivirals at non-toxic concentrations to the dead coronaviruses so as to form an immunogenic composition; and
administering the immunogenic composition to a patient in need thereof.